Skip to main content
. 2017 Mar 7;19(3):379–384. doi: 10.1007/s11307-017-1069-7

Fig. 1.

Fig. 1

Anti-CD8 immuno-PET in subcutaneous colorectal immunotherapy model. CT26 murine colon cancer-grafted mice were treated with CD137-agonistic Abs: CD137-treated, CD137-treated/CD8-blocked mice, and control mice (no anti-CD137 therapy) were injected with 89Zr-malDFO-169 cDb and immuno-PET images were acquired at 22 h postinjection. Note the presence of increased CD8+ tumor-infiltrating lymphocytes within the tumor in CD137-treated animal (white arrow, adapted from [56]).